Blog
About

26
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

      The Lancet Infectious Diseases

      epidemiology, diagnosis, microbiology, Antibiotics, Antitubercular, diagnostic use, Cost of Illness, Cost-Benefit Analysis, Drug Resistance, Bacterial, Global Health, Health Care Costs, Humans, Mycobacterium tuberculosis, drug effects, genetics, isolation & purification, Nucleic Acid Amplification Techniques, Point-of-Care Systems, trends, Predictive Value of Tests, Rifampin, Sputum, Tuberculosis, Multidrug-Resistant, drug therapy, mortality, Tuberculosis, Pulmonary, AIDS-Related Opportunistic Infections

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rapid progress has been made in the development of new diagnostic assays for tuberculosis in recent years. New technologies have been developed and assessed, and are now being implemented. The Xpert MTB/RIF assay, which enables simultaneous detection of Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in December, 2010. This assay was specifically recommended for use as the initial diagnostic test for suspected drug-resistant or HIV-associated pulmonary tuberculosis. By June, 2012, two-thirds of countries with a high tuberculosis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated the assay into their national tuberculosis programme guidelines. Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined. We review the rapidly growing body of scientific literature and discuss the advantages and challenges of using the Xpert MTB/RIF assay in areas where tuberculosis is endemic. We also review other prospects within the developmental pipeline. A rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed. Investment in the tuberculosis diagnostics pipeline should remain a major priority for funders and researchers. Copyright © 2013 Elsevier Ltd. All rights reserved.

          Related collections

          Author and article information

          Journal
          23531388
          10.1016/S1473-3099(13)70008-2

          Comments

          Comment on this article